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Abstract: Interventional studies have demonstrated the impact of hyperglycemia on the
development of vascular complications associated with type 2 diabetes, which underscores
the importance of safely lowering glucose to as near-normal as possible. Among the current
challenges to reducing the risk of vascular disease associated with diabetes is the management
of body weight in a predominantly overweight patient population, and in which weight gain
is likely with many current therapies. Exenatide is the first in a new class of agents termed
incretin mimetics, which replicate several glucoregulatory effects of the endogenous incretin
hormone, glucagon-like peptide-1 (GLP-1). Currently approved in the US as an injectable
adjunct to metformin and/or sulfonylurea therapy, exenatide improves glycemic control through
multiple mechanisms of action including: glucose-dependent enhancement of insulin secretion
that potentially reduces the risk of hypoglycemia compared with insulin secretagogues;
restoration of first-phase insulin secretion typically deficient in patients with type 2 diabetes;
suppression of inappropriately elevated glucagon secretion to reduce postprandial hepatic
output; and slowing the rate of gastric emptying to regulate glucose appearance into the
circulation. Clinical trials in patients with type 2 diabetes treated with subcutaneous exenatide
twice daily demonstrated sustained improvements in glycemic control, evidenced by reductions
in postprandial and fasting glycemia and glycosylated hemoglobin (HbA1c) levels. Notably,
improvements in glycemic control with exenatide were coupled with progressive reductions
in body weight, which represents a distinct therapeutic benefit for patients with type 2 diabetes.
Acute effects of exenatide on beta-cell responsiveness along with significant reductions in
body weight in patients with type 2 diabetes may have a positive impact on disease progression
and potentially decrease the risk of associated long-term complications.
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Type 2 diabetes and vascular disease
Vascular complications represent the leading cause of mortality and morbidity in
patients with diabetes (Morrish et al 2001). Approximately 65% of deaths among
patients with diabetes are due to cardiovascular and cerebrovascular diseases,
including myocardial ischemia and stroke (Haffner et al 1998; Klein 1999; Erdmann
2005). Adverse outcomes are also associated with microvascular diseases such as
nephropathy, neuropathy, and retinopathy, which contribute significantly to the
development of end-stage renal disease, foot ulcers, and blindness (Klein 1999;
Singleton et al 2003). Type 2 diabetes is the clinical manifestation of long-term
metabolic abnormalities involving multiple organs and hormonal pathways that impair
the body’s ability to maintain glucose homeostasis (Aronoff et al 2004). Pancreatic
beta-cell dysfunction and insulin resistance are widely recognized as the cardinal
defects that lead to chronic hyperglycemia, which is a major contributor of diabetic
vascular complications. At the cellular level, elevated glucose concentrations cause
increased production of reactive oxidant species (ROS) that ultimately contribute to
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the deterioration of vascular health through multiple
pathways (Brownlee 2005). Effects of hyperglycemia-
induced damage include endothelial dysfunction,
inflammation, and the promotion of atherogenic conditions
(Ceriello 2001; Ahmad et al 2005).
In parallel with impaired glucose homeostasis, patients
with type 2 diabetes often have an associated constellation
of cardiovascular disease (CVD) risk factors including
hypertension, abdominal obesity, atherogenic dyslipidemia
(characterized by hypertriglyceridemia and low levels of
high-density lipoprotein cholesterol [HDL-C]), chronic
inflammation, and alterations in thrombolytic parameters
(Kannel and McGee 1979; Reaven 1988; Beckman et al
2002; Erdmann 2005). It is not surprising that type 2 diabetes
has been implicated as a coronary heart disease (CHD) “risk
equivalent”, carrying an absolute risk for coronary heart
events similar to that for nondiabetic individuals with
established CHD (NCEP 2002).
Obesity is strongly associated with type 2 diabetes and
is present in approximately 80%–95% of type 2 diabetes
cases (Astrup 2001). Obesity also exacerbates the metabolic
abnormalities of type 2 diabetes, particularly hyperglycemia,
hyperlipidemia, and hypertension (Kannel and McGee 1979;
Maggio and Pi-Sunyer 1997). Additionally, the risk of
developing type 2 diabetes increases exponentially in
relation to body mass index (BMI) (Mokdad et al 2000).
This is particularly evident in children and adolescents, in
whom obesity is on the rise and the incidence of type 2
diabetes is nearing that of type 1 (Kaufmann 2002).
Management of weight gain in patients with type 2 diabetes,
particularly in those already overweight, is important to
improving glycemic control and reducing CV risk
(Anderson et al 2003).
Results from the United Kingdom Prospective Diabetes
Study (UKPDS) of intensively treated patients with type 2
diabetes demonstrated the beneficial impact of glycemic
control for reducing microvascular complications, and
implicated a role for hyperglycemia in macrovascular
disease (UKPDS 1998). Notably, these data indicated that
any improvement in glycemic control has a beneficial impact
in reducing diabetes-related complications (Stratton et al
2000). Near-normalization of glycemia is possible with
current diabetes therapies; however, patients continue to
experience excessive diurnal glucose fluctuations (Monnier
et al 2002; Hirsch 2005). In addition, a majority of therapies
are typically accompanied by undesired weight gain and an
increased risk of hypoglycemia, particularly when treatment
includes insulin and several oral antihyperglycemic agents
(DeFronzo 1999; Purnell and Weyer 2003). Therefore,
pharmacological agents that provide glycemic control with
a reduced risk of severe hypoglycemia and reductions in
body weight would present a distinct treatment option
compared with currently available therapies for patients with
type 2 diabetes.
Exenatide, an incretin mimetic
Glucagon-like peptide-1 (GLP-1) is an insulinotropic gut
hormone, or incretin, that is partly responsible for the more
robust insulin secretory response elicited by enteral glucose
administration compared with that measured after
isoglycemic intravenous glucose infusion (Perley and Kipnis
1967; Creutzfeldt 1979; Kreymann et al 1987). Partly due
to reduced postprandial secretion of GLP-1, patients with
type 2 diabetes exhibit an impaired incretin response
compared with individuals with normal glucose tolerance
(Nauck et al 1986; Toft-Nielsen et al 2001). Exogenous
administration of GLP-1 has been shown to elicit
glucoregulatory effects in patients with type 2 diabetes
(Nauck et al 1993; Zander et al 2002). More recently,
preclinical and clinical studies have shown that GLP-1 also
has salutary cardiovascular effects (Nystrom, Gonon, et al
2004; Bose et al 2005). In particular, clinical studies have
demonstrated that GLP-1 ameliorates endothelial
dysfunction in patients with type 2 diabetes with established
CHD, and can improve left ventricular heart function in
patients with acute myocardial infarction (Nikolaidis et al
2004; Nystrom, Gutniak, et al 2004). Despite these features,
the therapeutic potential of GLP-1 is limited due to its rapid
degradation by the ubiquitous enzyme, dipeptidyl peptidase-
IV (DPP-IV) (Nauck et al 1993; Deacon et al 1995; Zander
et al 2002). The circulating half-life of GLP-1 is
approximately 1–2 minutes, which precludes the
maintenance of therapeutic levels by subcutaneous dosing
(Drucker 2003). Several approaches have been undertaken
to develop agents that replicate or replace the actions of
GLP-1, which are in various stages of clinical development
(Holst 2002; Deacon 2004). The first of these GLP-1-like
molecules to receive regulatory approval for the treatment
of type 2 diabetes is the incretin mimetic, exenatide.
Exenatide (exendin-4) is a 39 amino acid peptide
originally isolated from the salivary secretions of the lizard
Heloderma suspectum (Gila monster) that is approved in
the US as an adjunctive therapy to metformin and/or
sulfonyureas in patients with type 2 diabetes (Eng et al 1992;
Nielsen et al 2004; BYETTA® prescribing information [PI],Vascular Health and Risk Management 2006:2(1) 71
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Amylin Pharmaceuticals Inc, San Diego, CA, USA).
Exenatide shares 53% amino acid sequence identity with
human GLP-1 and has been shown in vitro to mediate its
insulinotropic effects through binding to the GLP-1 receptor
on pancreatic beta cells (Eng et al 1992; Goke et al 1993).
Exenatide exhibits a higher potency (ED50 [effective dose
50]; acute dose-response in animal models) and longer
duration of action relative to GLP-1 largely due to its
pharmacokinetic profile (Young et al 1999; Kolterman et al
2005). Exenatide lacks a penultimate alanine that directs
DPP-IV cleavage, rendering it more proteolytically stable
than GLP-1 (Thum et al 2002). Also, significant differences
in clearance rates between GLP-1 and exenatide have been
reported, with the plasma clearance of exenatide approxi-
mately 10% that of GLP-1 (Parkes et al 2001). The
circulating half-life of exenatide is 2.4 hours and its effects
are detectable for approximately 6–8 hours post-
administration (Fineman et al 2003; Kolterman et al 2005;
BYETTA PI).
The glucoregulatory effects of exenatide are achieved
through a range of actions similar to native GLP-1, including
the enhancement of glucose-dependent insulin secretion;
suppression of inappropriately elevated postprandial
glucagon secretion; slowing of gastric emptying; and
reduction in food intake (Table 1) (reviewed in Nielsen et al
2004). In addition, exenatide restores insulin responses and
secretory patterns typically deficient and abnormal in
patients with type 2 diabetes (Fehse et al 2005). These
mechanisms work in concert to reduce fasting and
postprandial glucose concentrations by modulation of both
glucose appearance (slowing of gastric emptying,
suppression of glucagon secretion, reduction of food intake)
and glucose disposal (enhancement of insulin secretion) in
the circulation.
Clinical studies with exenatide
Glycemic effects
Prospective epidemiological studies have demonstrated the
relationship between the incidence of microvascular and
macrovascular disease and hyperglycemia (Coutinho et al
1999; Stratton et al 2000). Increased risk of vascular disease
is continuous and incrementally graded across fasting
plasma glucose (FPG) concentrations, plasma glucose
concentrations after an oral glucose challenge, and average
levels of glycemia (HbA1c) (Stratton et al 2000). In the
Norfolk cohort of the European Prospective Investigation
into Cancer and Nutrition (EPIC-Norfolk), levels of HbA1c
were found to be continuously related to the increased risk
of all-cause mortality, CVD, and ischemic disease, with a
1% increase in HbA1c associated with a 28% increase in the
risk of death (Khaw et al 2001). Increasing evidence has
emphasized the role of postchallenge hyperglycemia
measured either 1–2 hours after a glucose load as a direct
and independent risk factor for CVD beyond the risk
associated with FPG alone (Bonora and Muggeo 2001,
Ceriello 2005; Home 2005). In particular, the DECODE
(Diabetes Epidemiology: Collaborative Analysis of
Diagnostic Criteria in Europe) and Framingham Offspring
Study designated postchallenge hyperglycemia as an
independent risk factor for CVD (DECODE 2001; Meigs
et al 2002). Moreover, the prognostic significance of
postchallenge hyperglycemia is further supported by studies
indicating that impaired glucose tolerance (IGT), rather than
impaired fasting glucose (IFG), is a critical determinant of
fatal CVD (Barrett-Connor and Ferrara 1998; Tominaga et
al 1999; Califf et al 2003).
Numerous studies have established the effective
glucoregulatory actions of exenatide as evidenced by
reductions in FPG concentrations, postprandial plasma
glucose (PPG) concentrations, and HbA1c (Fineman et al
2003; Kolterman et al 2003; Buse et al 2004; DeFronzo et
al 2005; Kendall, Kim, et al 2005; Poon et al 2005). The
antihyperglycemic effects of exenatide are mediated by the
key actions of enhancement of glucose-dependent insulin
secretion, suppression of inappropriate glucagon secretion,
and slowing of gastric emptying.
Acute glucoregulatory effects of exenatide were
exemplified in a 28-day study in patients with type 2 diabetes
treated with diet, sulfonylureas, and/or metformin.
Compared with placebo, exenatide-treated patients showed
significant mean reductions from baseline in HbA1c of
approximately 0.9% (Fineman et al 2003). Reductions in
HbA1c were observable after 1 month of exenatide treatment,
a notable response given that HbA1c reflects sustained
glycemic changes over the preceding 3 months. Exenatide
treatment also resulted in marked reductions in postprandial
glycemia (Fineman et al 2003). Glucose profiles during
ingestion of a mixed meal showed significant postprandial
Table 1 Primary glucoregulatory actions of exenatide
￿ enhances glucose-dependent insulin secretion
￿ restores 1st phase insulin secretion
￿ slows gastric emptying
￿ suppresses inappropriate glucagon secretion
￿ reduces food intakeVascular Health and Risk Management 2006:2(1) 72
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glucose-lowering effects that were observable from the first
day of exenatide treatment compared with placebo, and were
sustained to day 28 (Fineman et al 2003). Since postprandial
hyperglycemia may be a stronger predictor of vascular
disease than elevated FPG concentrations in patients with
diabetes (Ceriello 2005; Home 2005), pharmacological
control of meal-time glucose concentrations with exenatide
has the potential to reduce the incidence of long-term
complications in patients with type 2 diabetes. Additional
effects reported for exenatide include reductions in the
magnitude of diurnal glucose excursions (Heine et al 2005)
and reductions in postprandial triglyceride concentrations
(Kolterman et al 2003).
Worsening beta-cell function is thought to be responsible
for the progressive deterioration in glycemic control that
occurs almost universally over time in patients with type 2
diabetes (Kahn 2000). Therefore, pharmacological agents
that have the potential to reduce demand on residual beta-
cell function and improve beta-cell responsiveness may
positively impact long-term patient outcomes related to
disease progression and development of vascular
complications. One of the principal actions of exenatide is
the enhancement of insulin secretion from beta cells (Egan
et al 2002). Of clinical significance is that the insulinotropic
effects of exenatide are glucose-dependent (Degn et al 2004).
In an acute study, patients receiving varying doses of
exenatide following an overnight fast showed dose-
dependent reductions in plasma glucose concentrations
during a subsequent 8-hour period while the prevailing
glucose concentration was elevated (Kolterman et al 2003).
As euglycemia was restored, basal insulinemia was re-
established (Kolterman et al 2003). Thus, physiological
glucose-sensing mechanisms assure that insulin secretion
is coupled to glycemia, resulting in a reduced risk of
hypoglycemia. This action of exenatide is in contrast to
insulin secretagogues such as sulfonylureas, which increase
insulin secretion regardless of glucose concentrations.
Early beta-cell dysfunction is manifested as a loss of the
first phase insulin secretion, a rapid burst of insulin in
response to an intravenous glucose bolus that is
characteristically absent in patients with IGT and type 2
diabetes (Caumo and Luzi 2004). In a study comparing
patients with type 2 diabetes with healthy individuals, both
first-phase insulin secretion and second-phase insulin
secretion were significantly increased in patients with type 2
diabetes treated with intravenous exenatide compared with
saline (Fehse et al 2005). Further, exenatide restored insulin
secretory patterns, typically lacking in patients with type 2
diabetes, to those observed in healthy subjects (Fehse et al
2005). Additional results from surrogate assays of beta-cell
function, such as the proinsulin to insulin ratio, suggested
improved beta-cell secretory function with exenatide
compared with placebo, providing further evidence of
exenatide-mediated improvements in beta-cell health
(Fineman et al 2003; Buse et al 2004; DeFronzo et al 2005).
The safety and efficacy of exenatide were demonstrated
in 3, 30-week clinical trials in approximately 1400 patients
with type 2 diabetes unable to achieve glycemic control with
metformin, a sulfonylurea, or both (Buse et al 2004;
DeFronzo et al 2005; Kendall, Riddle, et al 2005). All three
studies reported that 30 weeks of exenatide treatment,
administered subcutaneously at 5 µg or 10 µg twice daily,
resulted in significant reductions in HbA1c, FPG concen-
trations and postprandial plasma glucose concentrations
compared with placebo (Buse et al 2004; DeFronzo et al
2005; Kendall, Riddle, et al 2005). Mean reductions from
baseline in HbA1c ranged from –0.9 to –0.8% in the 10 µg
exenatide groups compared with mean increases of +0.1 to
+0.2% in the placebo groups (Figure 1). Consistent with
these results, a cohort of 393 patients completing 82 weeks
of exenatide treatment in open-label extensions of the
placebo-controlled trials showed sustained reductions in
HbA1c of approximately –1.1%, demonstrating the durability
of the exenatide treatment response (Blonde et al 2005).
In a phase 3, noninferiority study, exenatide was directly
compared with basal insulin (insulin glargine) in patients
with type 2 diabetes inadequately controlled with metformin
or sulfonylureas (Heine et al 2005). Results from the
26-week, open-label study showed that exenatide achieved
similar reductions in HbA1c to insulin glargine (exenatide:
–1.0%, glargine: –1.1%). Comparison of self-monitored
blood glucose profiles in treated patients showed
improvements in postprandial glucose control and in
24-hour glucose profiles with exenatide, whereas glargine
mainly lowered FPG concentrations, but did not alter the
magnitude of postprandial glucose excursions throughout
the day (Heine et al 2005). Results from this comparator
study indicate that exenatide may have a role as an
appropriate alternative to basal insulin in patients with type 2
diabetes failing to achieve treatment targets on combination
oral medications.
Weight effects
Excess weight causes deleterious effects on glucose
metabolism due predominantly to insulin resistance and
elevated levels of free fatty acids. Numerous studies haveVascular Health and Risk Management 2006:2(1) 73
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demonstrated that even modest weight loss (5% to 10%)
markedly improves glycemic control in patients with type 2
diabetes and reduces the severity of vascular risk factors
and comorbidities (Goldstein 1992; Williamson et al 2000;
Vidal 2002). It is well recognized that the cornerstone of
managing diabetes is diet and exercise modification to
achieve significant and sustained weight loss. Managing
body weight gain becomes increasingly challenging given
that intensive glucose control with most therapies may be
accompanied by substantial weight gain (Purnell and Weyer
2003).
Studies with exenatide demonstrate that improvements
in glycemic control in patients with type 2 diabetes are
accompanied by significant reductions in body weight (Buse
et al 2004; DeFronzo et al 2005; Kendall, Riddle, et al 2005).
In the placebo-controlled, 30-week trials, mean reductions
from baseline in body weight were observed, ranging from
–2.8 kg to –1.6 kg in the 10 µg dosing group after 30 weeks
of exenatide treatment, compared with +0.9 kg to +0.3 kg
in the placebo group (Figure 1) (Buse et al 2004; DeFronzo
et al 2005; Kendall, Riddle, et al 2005). Positive effects of
exenatide on body weight were further evident when
treatment effects were directly compared with those with
insulin glargine in the 26-week noninferiority study. Similar
reductions in HbA1c of approximately –1% were demon-
strated with each treatment, however, exenatide  treatment
resulted  in  a  mean  reduction  of –2.3 kg in body weight,
whereas glargine treatment resulted in a mean increase of
+1.8 kg in body weight (Heine et al 2005).
An interim assessment of ongoing, open-label extensions
of the 30-week, placebo-controlled trials, a subgroup of
patients completing 82 weeks of exenatide treatment
(n = 265) showed sustained mean reductions in HbA1c of
–1.2% and progressive reductions of body weight of –4.6 kg
(Figure 2) (Kendall, Kim, et al 2005). It is notable that this
body weight loss was observed without any protocol
specified diet and exercise advice, and with a concurrent
HbA1c reduction of approximately 1%. The impact of
reductions in HbA1c and body weight over 82 weeks was
further evaluated using several risk markers of CVD
(Table 2). Significant improvements from baseline to Week
82 in circulating concentrations of triglycerides, HDL-C,
and diastolic blood pressure were observed (Table 2)
(Kendall, Kim, et al 2005). Additional analyses explored
parameters by quartiles wherein the cohort was subdivided
into 4 equal-sized groups based on their absolute change in
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Figure 1 Results from pivotal studies with exenatide. Mean ± SE changes from baseline in glycemia and body weight in patients with type 2 diabetes treated with
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weight. Findings from this analysis showed that the quartile
with the greatest reduction in weight showed the greatest
improvements in cardiovascular risk factors (Kendall, Kim,
et al 2005). Therefore, sustained improvements in glycemic
control and progressive reductions in body weight with
exenatide treatment were associated with shifts toward a
more favourable cardiovascular risk profile, particularly in
patients that experienced the greatest weight loss. Whether
exenatide exhibits direct cardiovascular effects similar to
GLP-1 is currently unknown.
Safety
Across the pivotal clinical trials, exenatide was generally
well tolerated. Adverse events were mostly gastrointestinal
in nature (nausea and vomiting) (Buse et al 2004; DeFronzo
et al 2005; Kendall, Riddle, et al 2005; BYETTA 2005).
Nausea, the most common treatment-emergent adverse event
(exenatide 44%, placebo 18%), was mostly mild to moderate
in intensity and diminished over time. Withdrawal due to
nausea was approximately 4%.
Consistent with its glucose-dependent mechanism of
action, most episodes of hypoglycemia were mild to
moderate in intensity with one severe event that did not
require medical assistance. Hypoglycemia was rarely
observed in patients treated with the combination of
exenatide and metformin and was similar in incidence to
patients treated with placebo and metformin (exenatide
10 µg, 5%; placebo, 5%) (DeFronzo et al 2005). In contrast,
the incidence of hypoglycemia was increased over that of
placebo when exenatide was used in combination with a
sulfonylurea (exenatide 10 µg, 32%; placebo, 8%) (Buse et
al 2004; Kendall, Riddle, et al 2005). Initial reduction of
sulfonylurea dosage may limit the risk of hypoglycemia
associated with such therapies upon initiation of exenatide
treatment (Kendall, Riddle, et al 2005).
Approximately 40% of exenatide-treated patients
developed anti-exenatide antibodies irrespective of
background therapy (Buse et al 2004; DeFronzo et al 2005;
Kendall, Riddle, et al 2005). The majority of these antibodies
were of low-titer with no apparent clinical consequence. A
small proportion of exenatide-treated patients (6%)
developed high-titer antibodies (≥ 1/625), of which 3%
showed attenuated glycemic effects and 3% did not
(BYETTA 2005). These findings, along with those from
Table 2 Mean (±SE) change from baseline to 82 weeks in lipids and sitting blood pressure (n=265) (Kendall, Kim, et al 2005)
Parameter Baseline Δ Δ Δ Δ Δ From baseline 95% confidence
(± SE) (± SE) interval
TC (mmol/L) 4.82 ± 0.06 –0.07 ± 0.05 –0.17, +0.04
HDL-C (mmol/L) 0.98 ± 0.01 +0.12 ± 0.01 +0.09, +0.14
LDL-C (mmol/L) 2.98 ± 0.06 –0.04 ± 0.05 –0.13, +0.06
Apo B (g/L) 0.92 ± 0.02 –0.01 ± 0.01 –0.04, +0.01
Triglycerides (mmol/L) 2.70 ± 0.13 –0.42 ± 0.11 –0.63, –0.20
Systolic blood pressure (mmHg) 128.59 ± 0.84 –1.48 ± 1.01 –3.46, +0.51
Diastolic blood pressure (mmHg) 78.66 ± 0.48 –3.24 ± 0.58 –4.37, –2.10
Abbreviations: Apo B, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.
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Figure 2 Mean ± SE change from baseline in glycemia (HbA1c) (%) and body weight over 82 weeks of 10 µg exenatide treatment in open-label extension studies of
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recent trials, indicate that the presence of antibodies is not
predictive of the magnitude of clinical response, incidence,
or type of adverse events.
Summary
Exenatide is a first in class incretin mimetic agent currently
approved in the US as an adjunct to metformin and/or
sulfonylureas for the treatment of type 2 diabetes. Exenatide
improves glycemic control in patients with type 2 diabetes
by significantly reducing HbA1c, and both fasting and
postprandial hyperglycemia, through multiple mechanisms
of action. The actions of exenatide include acute beta-cell
effects (enhancement of glucose-dependent insulin
secretion; restoration of first-phase insulin secretion),
regulation of inappropriately elevated glucagon secretion,
slowing of gastric emptying, and reduction of food intake.
Mounting evidence implicates post-meal hyperglycemia as
a stronger predictor of the development of vascular
complications than FPG. Since aberrant first-phase insulin
secretion and impaired suppression of endogenous glucose
production are major contributors to postprandial
hyperglycemia, the effects of exenatide to target these
defects, and normalize glucose excursions in patients with
type 2 diabetes are likely to be clinically significant.
Obesity, the development of type 2 diabetes, and vascular
risk are strongly linked. There is increasing evidence that
weight loss can be beneficial in both the prevention and
treatment of type 2 diabetes, but it is also recognized that
this is difficult to achieve in a majority of patients.
Improvements in glycemic control with exenatide were
coupled with progressive weight reductions, which
represents a distinct therapeutic benefit for patients with
type 2 diabetes not adequately controlled with metformin
and/or sulfonylurea therapy. In particular, potential
reductions in body weight in patients with type 2 diabetes
may have a positive impact on the development of vascular
complications and long-term patient outcomes.
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